A detailed history of Price T Rowe Associates Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 34,784 shares of SAVA stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,784
Previous 31,327 11.04%
Holding current value
$1.02 Million
Previous $636,000 32.39%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$12.35 - $26.11 $42,693 - $90,262
3,457 Added 11.04%
34,784 $430,000
Q1 2024

May 15, 2024

BUY
$18.44 - $26.41 $26,848 - $38,452
1,456 Added 4.87%
31,327 $636,000
Q4 2023

Feb 14, 2024

BUY
$12.64 - $30.11 $28,844 - $68,711
2,282 Added 8.27%
29,871 $673,000
Q3 2023

Nov 14, 2023

BUY
$16.64 - $25.32 $14,476 - $22,028
870 Added 3.26%
27,589 $460,000
Q2 2023

Aug 14, 2023

SELL
$21.59 - $27.88 $5,354 - $6,914
-248 Reduced 0.92%
26,719 $656,000
Q1 2023

May 15, 2023

BUY
$23.46 - $36.44 $36,738 - $57,065
1,566 Added 6.17%
26,967 $651,000
Q4 2022

Feb 14, 2023

SELL
$27.82 - $44.16 $66,211 - $105,100
-2,380 Reduced 8.57%
25,401 $750,000
Q3 2022

Nov 14, 2022

BUY
$16.33 - $51.06 $15,170 - $47,434
929 Added 3.46%
27,781 $1.16 Million
Q2 2022

Aug 15, 2022

SELL
$17.22 - $38.47 $23,987 - $53,588
-1,393 Reduced 4.93%
26,852 $755,000
Q1 2022

May 16, 2022

BUY
$32.6 - $53.05 $174,214 - $283,499
5,344 Added 23.34%
28,245 $1.05 Million
Q4 2021

Feb 14, 2022

BUY
$36.77 - $90.91 $60,266 - $149,001
1,639 Added 7.71%
22,901 $1 Million
Q3 2021

Nov 15, 2021

SELL
$41.79 - $135.3 $27,038 - $87,539
-647 Reduced 2.95%
21,262 $1.32 Million
Q2 2021

Aug 16, 2021

SELL
$32.15 - $89.72 $443,573 - $1.24 Million
-13,797 Reduced 38.64%
21,909 $1.87 Million
Q1 2021

May 17, 2021

BUY
$7.09 - $87.95 $157,461 - $1.95 Million
22,209 Added 164.55%
35,706 $1.61 Million
Q4 2020

Feb 16, 2021

BUY
$6.79 - $12.25 $91,644 - $165,338
13,497 New
13,497 $92,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.18B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.